Quickly cleans the intestines without affecting the absorption or excretion of ions or water

Quickly cleans the intestines without affecting the absorption or excretion of ions or water

Quickly cleans the intestines without affecting the absorption or excretion of ions or water

Quickly cleans the intestines without affecting the absorption or excretion of ions or water

Osmotically active, quickly cleanses the intestines without affecting the absorption or excretion of ions or water

The osmotic activity of polyethylene glycol 4000 and the concentration of electrolytes do not affect the absorption or excretion of ions or water. Large-scale application does not significantly change the fluid or electrolyte balance.

No specific pharmacological effects mentioned

No specific pharmacological effects mentioned

No specific pharmacological effects mentioned

No specific pharmacological effects mentioned

Erythromycin is a macrolide antibiotic. Common sensitive strains include group A Streptococcus, Streptococcus mitis, Streptococcus sanguinis, Pneumococcus, Neisseria meningitidis, Neisseria gonorrhoeae, Bordetella pertussis, Moraxella catarrhalis, Corynebacterium diphtheriae, Listeria monocytogenes, Clostridium difficile, Mycoplasma pneumoniae, Chlamydia trachomatis, Legionella, Treponema pallidum, Leptospira, and Campylobacter. Strains with variable sensitivity include Haemophilus influenzae, Bacteroides fragilis, Clostridium cholerae, and Staphylococcus aureus. Enterobacteriaceae and Pseudomonas are resistant strains.

This product belongs to the macrolide antibiotics. It inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome of sensitive bacteria. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), streptococci of all groups and Gram-positive bacilli. Streptococcus pyogenes, group A hemolytic streptococci, Staphylococcus, Streptococcus pneumoniae, meningococci, gonorrhea, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Mycoplasma pneumoniae, Chlamydia, Legionella, Treponema pallidum, Leptospira, and Campylobacter fetus. Non-clinical toxicology studies: In long-term (2-year) studies on rats, oral erythromycin has no evidence of carcinogenicity or gene mutation; studies on male and female rats have not found any effects on reproduction.

It achieves antibacterial effect by inhibiting the activity of bacterial topoisomerase IV and DNA gyrase, hindering the replication of bacterial DNA. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, but has poor effect on anaerobic bacteria and enterococci.